Trisomy 21 and early brain development

Trends in Neurosciences

Volumn 35, Issue 2, 2012, Pages 81-91

  Haydar, Tarik F ^a   Reeves, Roger H ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1A; GLUTAMATE RECEPTOR; NEURON RESTRICTIVE SILENCER FACTOR; PARVALBUMIN; PROTEIN; SOMATOSTATIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

BRAIN CORTEX; BRAIN DEVELOPMENT; BRAIN ELECTROPHYSIOLOGY; BRAIN MALFORMATION; BRAIN NERVE CELL; CENTRAL NERVOUS SYSTEM; CEREBELLUM; DOWN SYNDROME; EMBRYO DEVELOPMENT; FOREBRAIN; GENE DOSAGE; HIPPOCAMPUS; LEARNING; MEMORY; NERVE CELL EXCITABILITY; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SUBVENTRICULAR ZONE; SYNAPTOGENESIS; TRISOMY 21;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOWN SYNDROME; HUMANS; MICE;

EID: 84856508563     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2011.11.001     Document Type: Review

References (127)

1. Canfield M.A., et al. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res. A: Clin. Mol. Teratol. 2006, 76:747-756.
2. Ferencz C., et al. Congenital cardiovascular malformations associated with chromosome abnormalities: an epidemiologic study. J. Pediatr. 1989, 114:79-86.
3. Levy J. The gastrointestinal tract in Down syndrome. Prog. Clin. Biol. Res. 1991, 373:245-256.
4. Fischer-Brandies H. Cephalometric comparison between children with and without Down's syndrome. Eur. J. Orthodont. 1988, 10:255-263.
5. Frostad W., et al. Craniofacial complex in the trisomy 21 syndrome (Down's syndrome). Arch. Oral Biol. 1971, 16:707-722.
6. Wechsler J., et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat. Genet. 2002, 32:148-152.
7. Yang Q., et al. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002, 359:1019-1025.
8. Chapman R.S., Hesketh L.J. Behavioral phenotype of individuals with Down syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 2000, 6:84-95.
9. Reeves R.H., Garner C.C. A year of unprecedented progress in Down syndrome basic research. Ment. Retard. Dev. Disabil. Res. Rev. 2007, 13:215-220.
10. Wetmore D.Z., Garner C.C. Emerging pharmacotherapies for neurodevelopmental disorders. J. Dev. Behav. Pediatr. 2010, 31:564-581.
11. A receptors in aging, Down syndrome and Alzheimer's disease. J. Neurochem. 2011, 117:613-622.
12. Golden J.A., Hyman B.T. Development of the superior temporal neocortex is anomalous in trisomy 21. J. Neuropathol. Exp. Neurol. 1994, 53:513-520.
13. Sylvester P.E. The hippocampus in Down's syndrome. J. Ment. Defic. Res. 1983, 27:227-236.
14. Aylward E.H., et al. Cerebellar volume in adults with Down syndrome. Arch. Neurol. 1997, 54:209-212.
15. Baxter L.L., et al. Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Hum. Mol. Genet. 2000, 9:195-202.
16. Crome R., et al. A statistical note on cerebellar and brain-stem weight in Down syndrome. J. Ment. Defect Res. 1966, 10:69-72.
17. Jernigan T.L., Bellugi U. Anomalous brain morphology on magnetic resonance images in Williams syndrome and Down syndrome. Arch. Neurol. 1990, 47:529-533.
18. Raz N., et al. Selective neuroanatomic abnormalities in Down's syndrome and their cognitive correlates: evidence from MRI morphometry. Neurology 1995, 45:356-366.
19. Becker L.E., et al. Dendritic atrophy in children with Down's syndrome. Ann. Neurol. 1986, 20:520-526.
20. Benavides-Piccione R., et al. On dendrites in Down syndrome and DS murine models: a spiny way to learn. Prog. Neurobiol. 2004, 74:111-126.
21. Takashima S., et al. Dendrites, dementia and the Down syndrome. Brain Dev. 1989, 11:131-133.
22. Petit T.L., et al. Synaptic development in the human fetus: a morphometric analysis of normal and Down's syndrome neocortex. Exp. Neurol. 1984, 83:13-23.
23. Weitzdoerfer R., et al. Fetal life in Down syndrome starts with normal neuronal density but impaired dendritic spines and synaptosomal structure. J. Neural. Transm. Suppl. 2001, 61:59-70.
24. Schmidt-Sidor B., et al. Brain growth in Down syndrome subjects 15 to 22 weeks of gestational age and birth to 60 months. Clin. Neuropathol. 1990, 9:181-190.
25. Marin-Padilla M. Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome. A Golgi study. J. Comp. Neurol. 1976, 167:63-81.
26. Zellweger H. Down syndrome. In Handbook of Clinical Neurology 1977, North-Holland, 367-469.
27. Kimura M., et al. Proliferation dynamics in cultured skin fibroblasts from Down syndrome subjects. Free Radic. Biol. Med. 2005, 39:374-380.
28. Schneider E.L., Epstein C.J. Replication rate and lifespan of cultured fibroblasts in Down's syndrome. Proc. Soc. Exp. Biol. Med. 1972, 141:1092-1094.
29. Bernert G., et al. Decreased cyclin dependent kinase in brain of patients with Down syndrome. Neurosci. Lett. 1996, 216:68-70.
30. Guidi S., et al. Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathol. 2008, 18:180-197.
31. Guidi S., et al. Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with down syndrome. Brain Pathol. 2011, 21:361-373.
32. Potier M.C., et al. Transcriptional disruptions in Down syndrome: a case study in the Ts1Cje mouse cerebellum during post-natal development. J. Neurochem. 2006, 97(Suppl. 1):104-109.
33. Roper R.J., Reeves R.H. Understanding the basis for Down syndrome phenotypes. PLoS Genet. 2006, 2:e50.
34. Pletcher M.T., et al. Use of comparative physical and sequence mapping to annotate mouse chromosome 16 and human chromosome 21. Genomics 2001, 74:45-54.
35. Reeves R., et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 1995, 11:177-183.
36. O'Doherty A., et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 2005, 309:2033-2037.
37. Yu T., et al. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum. Mol. Genet. 2010, 19:2780-2791.
38. Gardiner K.J. Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends Pharmacol. Sci. 2010, 31:66-73.
39. Mo Z., et al. Human cortical neurons originate from radial glia and neuron-restricted progenitors. J. Neurosci. 2007, 27:4132-4145.
40. Kahlem P., et al. Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of Down syndrome. Genome Res. 2004, 14:1258-1267.
41. Das I., Reeves R.H. The use of mouse models to understand and improve cognitive deficits in Down syndrome. Disease Models and Mechanisms 2011, 4:596-606.
42. Bradford H.F. Glutamate, GABA and epilepsy. Prog. Neurobiol. 1995, 47:477-511.
43. Haydar T.F. Advanced microscopic imaging methods to investigate cortical development and the etiology of mental retardation. Ment. Retard. Dev. Disabil. Res. Rev. 2005, 11:303-316.
44. Jamain S., et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat. Genet. 2003, 34:27-29.
45. Thompson S.M., et al. Mechanisms underlying the neuropathological consequences of epileptic activity in the rat hippocampus in vitro. J. Comp. Neurol. 1996, 372:515-528.
46. Rakic P. Mode of cell migration to the superficial layers of fetal monkey neocortex. J. Comp. Neurol. 1972, 145:61-83.
47. Corbin J.G., et al. Telencephalic cells take a tangent: non-radial migration in the mammalian forebrain. Nat. Neurosci. 2001, 4(Suppl.):1177-1182.
48. de Carlos J.A., et al. Dynamics of cell migration from the lateral ganglionic eminence in the rat. J. Neurosci. 1996, 16:6146-6156.
49. Anderson S.A., et al. Interneuron migration from basal forebrain to neocortex: dependence on Dlx genes. Science 1997, 278:474-476.
50. Tamamaki N., et al. Origin and route of tangentially migrating neurons in the developing neocortical intermediate zone. J. Neurosci. 1997, 17:8313-8323.
51. Ang E.S., et al. Four-dimensional migratory coordinates of GABAergic interneurons in the developing mouse cortex. J. Neurosci. 2003, 23:5805-5815.
52. Fairen A., et al. Times of generation of glutamic acid decarboxylase immunoreactive neurons in mouse somatosensory cortex. J. Comp. Neurol. 1986, 251:67-83.
53. Miller M.W. Cogeneration of retrogradely labeled corticocortical projection and GABA-immunoreactive local circuit neurons in cerebral cortex. Brain Res. 1985, 355:187-192.
54. Rakic P. Neurons in rhesus monkey visual cortex: systematic relation between time of origin and eventual disposition. Science 1974, 183:425-427.
55. Valcanis H., Tan S.S. Layer specification of transplanted interneurons in developing mouse neocortex. J. Neurosci. 2003, 23:5113-5122.
56. Xu Q., et al. Origins of cortical interneuron subtypes. J. Neurosci. 2004, 24:2612-2622.
57. Contestabile A., et al. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with down syndrome and in Ts65Dn mice. Hippocampus 2007, 17:665-678.
58. Chakrabarti L., et al. Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nat. Neurosci. 2010, 13:927-934.
59. Chakrabarti L., et al. Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. J. Neurosci. 2007, 27:11483-11495.
60. Haydar T.F., et al. Consequences of trisomy 16 for mouse brain development: corticogenesis in a model of Down syndrome. J. Neurosci. 1996, 16:6175-6182.
61. Cheng A., et al. Concurrent generation of subplate and cortical plate neurons in developing trisomy 16 mouse cortex. Dev. Neurosci. 2004, 26:255-265.
62. Dowjat W.K., et al. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. Neurosci. Lett. 2007, 413:77-81.
63. Fuentes J.J., et al. Genomic organization, alternative splicing, and expression patterns of the DSCR1 (Down syndrome candidate region 1) gene. Genomics 1997, 44:358-361.
64. Guimera J., et al. A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region. Hum. Mol. Genet. 1996, 5:1305-1310.
65. Park J., et al. Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell Mol. Life Sci. 2009, 66:3235-3240.
66. Song W.J., et al. Isolation of human and murine homologues of the Drosophila minibrain gene: human homologue maps to 21q22.2 in the Down syndrome 'critical region'. Genomics 1996, 38:331-339.
67. Hammerle B., et al. The spatio-temporal and subcellular expression of the candidate Down syndrome gene Mnb/Dyrk1A in the developing mouse brain suggests distinct sequential roles in neuronal development. Eur. J. Neurosci. 2008, 27:1061-1074.
68. Hammerle B., et al. Mnb/Dyrk1A is transiently expressed and asymmetrically segregated in neural progenitor cells at the transition to neurogenic divisions. Dev. Biol. 2002, 246:259-273.
69. Okui M., et al. High-level expression of the Mnb/Dyrk1A gene in brain and heart during rat early development. Genomics 1999, 62:165-171.
70. Fotaki V., et al. Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol. Cell. Biol. 2002, 22:6636-6647.
71. Moller R.S., et al. Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly. Am. J. Hum. Genet. 2008, 82:1165-1170.
72. Fernandez-Martinez J., et al. Attenuation of notch signalling by the Down-syndrome-associated kinase DYRK1A. J. Cell Sci. 2009, 122:1574-1583.
73. Kinstrie R., et al. dDYRK2 and Minibrain interact with the chromatin remodelling factors SNR1 and TRX. Biochem. J. 2006, 398:45-54.
74. Lepagnol-Bestel A.M., et al. DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome. Hum. Mol. Genet. 2009, 18:1405-1414.
75. Maenz B., et al. Characterization of the human DYRK1A promoter and its regulation by the transcription factor E2F1. BMC Mol. Biol. 2008, 9:30.
76. Raich W.B., et al. Characterization of Caenorhabditis elegans homologs of the Down syndrome candidate gene DYRK1A. Genetics 2003, 163:571-580.
77. Yabut O., et al. Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells. J. Neurosci. 2010, 30:4004-4014.
78. Yang E.J., et al. Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells. J. Biol. Chem. 2001, 276:39819-39824.
79. Dierssen M., de Lagran M.M. DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A): a gene with dosage effect during development and neurogenesis. ScientificWorldJournal 2006, 6:1911-1922.
80. Altafaj X., et al. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum. Mol. Genet. 2001, 10:1915-1923.
81. Martinez de Lagran M., et al. Motor phenotypic alterations in TgDyrk1a transgenic mice implicate DYRK1A in Down syndrome motor dysfunction. Neurobiol. Dis. 2004, 15:132-142.
82. Tejedor F.J., Hammerle B. MNB/DYRK1A as a multiple regulator of neuronal development. FEBS J. 2010, 278:223-235.
83. Kleschevnikov A.M., et al. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 2004, 24:8153-8160.
84. Hanson J.E., et al. The functional nature of synaptic circuitry is altered in area CA3 of the hippocampus in a mouse model of Down's syndrome. J. Physiol. 2007, 579:53-67.
85. Fernandez F., et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 2007, 10:411-413.
86. Butt S.J., et al. The temporal and spatial origins of cortical interneurons predict their physiological subtype. Neuron 2005, 48:591-604.
87. Flames N., et al. Delineation of multiple subpallial progenitor domains by the combinatorial expression of transcriptional codes. J. Neurosci. 2007, 27:9682-9695.
88. Nery S., et al. The caudal ganglionic eminence is a source of distinct cortical and subcortical cell populations. Nat. Neurosci. 2002, 5:1279-1287.
89. Olson L.E., et al. A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 2004, 306:687-690.
90. Belichenko N.P., et al. The 'Down syndrome critical region' is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J. Neurosci. 2009, 29:5938-5948.
91. Davidoff L.M. The brain in Mongolian idiocy. Arch. Neurol. Psychiatry 1928, 20:1229-1268.
92. Hyde L.A., et al. Motor learning in Ts65Dn mice, a model for Down syndrome. Dev. Psychobiol. 2001, 38:33-45.
93. Costa A.C., et al. Motor dysfunction in a mouse model for Down syndrome. Physiol. Behav. 1999, 68:211-220.
94. Galante M., et al. Impairments in motor coordination without major changes in cerebellar plasticity in the Tc1 mouse model of Down syndrome. Hum. Mol. Genet. 2009, 18:1449-1463.
95. Dahmane N., Ruiz-i-Altaba A. Sonic hedgehog regulates the growth and patterning of the cerebellum. Development 1999, 126:3089-3100.
96. Wallace V.A. Purkinje-cell-derived sonic hedgehog regulates granule neuron precursor cell proliferation in the developing mouse cerebellum. Curr. Biol. 1999, 9:445-448.
97. Wechsler-Reya R.J., Scott M.P. Control of neuronal precursor proliferation in the cerebellum by sonic hedgehog. Neuron 1999, 22:103-114.
98. Roper R.J., et al. Defective cerebellar response to mitogenic hedgehog signaling in Down syndrome mice. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1452-1456.
99. Chen J.K., et al. Small molecule modulation of smoothened activity. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:14071-14076.
100. Frank-Kamenetsky M., et al. Small-molecule modulators of hedgehog signaling: identification and characterization of smoothened agonists and antagonists. J. Biol. 2002, 1:10.
101. Costa A.C. An assessment of the vestibulo-ocular reflex (VOR) in persons with Down syndrome. Exp. Brain Res. 2011, 214:199-213.
102. Migliaccio A.A., et al. Characterization of the 3D angular vestibulo-ocular reflex in C57BL6 mice. Exp. Brain Res. 2011, 210:489-501.
103. Burguiere E., et al. Role of the cerebellar cortex in conditioned goal-directed behavior. J. Neurosci. 2010, 30:13265-13271.
104. Rondi-Reig L., Burguiere E. Is the cerebellum ready for navigation?. Prog. Brain Res. 2005, 148:199-212.
105. Trazzi S., et al. APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. Hum. Mol. Genet. 2011, 20:1560-1573.
106. Olson L.E., et al. Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes. Dev. Dyn. 2004, 230:581-589.
107. Ma'ayan A., et al. The cognitive phenotype of Down syndrome: insights from intracellular network analysis. NeuroRx 2006, 3:396-406.
108. Lejeune J., et al. Etudes des chromosomes somatiques de neuf enfants mongoliens. C.R. Acad. Sci. (Paris) 1959, 248:1721-1722.
109. Pennington B.F., et al. The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev. 2003, 74:75-93.
110. Edgin J.O., et al. Development and validation of the Arizona Cognitive Test Battery for Down syndrome. J. Neurodev. Disord. 2010, 2:149-164.
111. Braudeau J., et al. Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J. Psychopharmacol. 2011, 25:1030-1042.
112. Guedj F., et al. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS ONE 2009, 4:e4606.
113. Olson L.E., et al. A chromosome 21 critical region does not cause specific down syndrome phenotypes. Science 2004, 306:687-690.
114. Sago H., et al. Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:6256-6261.
115. Koo B.K., et al. Magnetic resonance imaging evaluation of delayed myelination in Down syndrome: a case report and review of the literature. J. Child. Neurol. 1992, 7:417-421.
116. Wisniewski K.E., Schmidt-Sidor B. Postnatal delay of myelin formation in brains from Down syndrome infants and children. Clin. Neuropathol. 1989, 8:55-62.
117. Sturgeon X., Gardiner K.J. Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm. Genome 2011, 22:261-271.
118. Vilardell M., et al. Meta-analysis of heterogeneous Down syndrome data reveals consistent genome-wide dosage effects related to neurological processes. BMC Genomics 2011, 12:229.
119. Salehi A., et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 2006, 51:29-42.
120. Lipsky R.H., Goldman D. Genomics and variation of ionotropic glutamate receptors. Ann. N. Y. Acad. Sci. 2003, 1003:22-35.
121. Buccafusca R., et al. Characterization of the null murine sodium/myo-inositol cotransporter 1 (Smit1 or Slc5a3) phenotype: myo-inositol rescue is independent of expression of its cognate mitochondrial ribosomal protein subunit 6 (Mrps6) gene and of phosphatidylinositol levels in neonatal brain. Mol. Genet. Metab. 2008, 95:81-95.
122. Rezai Z., Yoon C.H. Abnormal rate of granule cell migration in the cerebellum of 'Weaver' mutant mice. Dev. Biol. 1972, 29:17-26.
123. Westmark C.J., Malter J.S. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 2007, 5:e52.
124. Cramer N.P., et al. GABAB-GIRK2-mediated signaling in Down syndrome. Adv. Pharmacol. 2010, 58:397-426.
125. Arron J.R., et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 2006, 441:595-600.
126. Martin L.J. Transgenic mice with human mutant genes causing Parkinson's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration. Rev. Neurosci. 2007, 18:115-136.
127. Salehi A., et al. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci. Transl. Med. 2009, 1:7ra17.